Business Wire

ATHORA-HOLDING

6.4.2021 08:02:09 CEST | Business Wire | Press release

Share
Athora Announces Full Year 2020 Results

Athora Holding Ltd. (Athora), an insurance and reinsurance group focused on the European market, delivered a solid performance and saw significant growth in 2020. During the year ending 31 December 2020, assets under administration grew to €83 billion, organic capital generation increased in our Belgian and German business units, and the group was pleased to report a strong inaugural estimated Bermuda Solvency Capital Requirement (BSCR) ratio of 242%.

Performance Highlights

  • Assets under administration of €83 billion (2019: €15 billion) boosted by the transformative acquisition of Athora Netherlands (formerly VIVAT). The group now supports over 2.5 million policyholders
  • Group IFRS profit before tax (from continuing operations) for the year of €700 million (2019: €13 million loss). This was primarily attributable to the consolidation of Athora Netherlands for the nine months post-acquisition in April 2020 and gain on acquisition of €213 million
  • Strong organic capital generation (OCG) in two business units well advanced in their integrations, Belgium and Germany, of €185 million (2019: €54 million) supported by asset optimisation and efficiency initiatives
  • IFRS total equity of €4.3 billion (2019: €0.6 billion) largely attributable to the issuance of €2.8 billion of additional equity share capital and IFRS net income1

Financial Strength Highlights

  • Inaugural group estimated BSCR ratio of 242%, following group supervision by the Bermuda Monetary Authority in 2020
  • Successfully raised €1.8 billion of additional equity capital commitments from new and existing shareholders
  • Completed €589 million Senior Bond tender in April reducing Athora Netherlands’ financial leverage
  • Group financial leverage ratio reduced to 26%

Strategic Progress

  • Effectively navigated the challenges posed by Covid-19 with 98% of employees able to work from home, undisrupted customer service and successful asset re-deployment at attractive returns
  • Acquisition of Athora Netherlands enabled Athora to reach critical mass, with significant growth potential
  • Successfully sold strategically non-core assets in Netherlands and Belgium
  • Growing reinsurance track-record following inaugural external reinsurance transaction in December with a leading Irish life insurer
  • Committed to developing our sustainability approach into an holistic ESG strategy for the group

Commenting on the results, Athora Group Chief Executive Officer, Michele Bareggi said:

"2020 was a year of significant progress and growth for this group, despite pandemic related disruption and challenging financial markets. Our solid performance reflects the merits of our business model, together with the added value that our strategic relationship with Apollo brings. We are particularly pleased to have delivered increased organic capital generation in Germany and Belgium, two business units well advanced in the integration of our business model. This resulted in robust closing capital positions in those entities and supported leading levels of customer returns. Financial stability is at the core of our business model as can be seen through our strong 2020 year-end capital position and group estimated BSCR ratio of 242%.

We have completed the first stage of our group’s strategic journey - achieving a critical mass with further potential to grow through the purchase of the second largest life insurer in the Netherlands – and we continue to be focused on supporting local management teams deliver the business case of each business unit including asset redeployment, very focused and effective operations, and selective growth.

I want to thank our employees for their hard work and determination in continuing to shape Athora into a leading life insurance and reinsurance group in Europe. By focusing on our mission, and despite the challenges brought by 2020, they remain committed to serving our over 2.5 million customers, and ensuring that our operations remain resilient. Thanks to their dedication and resourcefulness, we are already demonstrating the value of our business model having achieved more than expected in three years since becoming an independent group.

I look to 2021 with confidence, secure in the knowledge that we are building the right ecosystem to capitalise on the growth opportunities that are available to our group. Thanks to our strong capital position, strategic relationships and supportive investors who share our long-term vision, we are well positioned to capture these opportunities and continue to deliver more value for stakeholders.

About Athora
Athora is a specialised insurance and reinsurance group fully focused on the European market. We concentrate on the large and attractive traditional life and pensions market, with an ambition to become a leading provider of guaranteed life and pensions products in Europe. We serve the needs of individual and corporate customers who continue to demand products offering safety of returns, and also provide innovative M&A and reinsurance solutions to other insurers seeking to enhance their capital position or enact strategic change. Athora's principal subsidiaries are Athora Netherlands N.V. (Amstelveen, Netherlands), Athora Belgium N.V./S.A. (Brussels), Athora Lebensversicherung AG (Wiesbaden, Germany), Athora Ireland plc (Dublin) and Athora Life Re Ltd. (Bermuda). The Athora group employs 2,300 staff and has 2.6 million policyholders with assets under administration of €83 billion (as at 31 December 2020).

For more information, please visit: www.athora.com
LinkedIn: www.linkedin.com/company/athoragroup

(1) In 2020, Athora called €2.8 billion of equity capital comprising €1.5 billion from its first capital raise and €1.3 billion from its second capital raise.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Fujirebio and Sysmex Begin Sales Collaboration for Dementia Testing5.2.2026 07:30:00 CET | Press release

Fujirebio Holdings, Inc. (HQ: Minato-ku, Tokyo; President & CEO: Goki Ishikawa; “Fujirebio”), a consolidated subsidiary of H.U. Group Holdings, Inc. (HQ: Minato-ku, Tokyo; Chairman, President and Group CEO: Shigekazu Takeuchi) and Sysmex Corporation (HQ: Kobe, Japan; President: Kaoru Asano, “Sysmex”) have agreed on a sales collaboration for dementia testing. This agreement follows continued discussions based on the Basic Agreement on Business Collaboration in the Field of Immunoassay concluded in October 2023.1 Sysmex will exclusively sell Fujirebio's fully automated Lumipulse® immunoassay systems and dementia-related reagents ("the Products") in regions and countries mutually agreed upon by both companies. Going forward, Fujirebio and Sysmex will collaborate to meet the growing testing needs accompanying the wider adoption of therapeutic drugs and will gradually expand the countries where the Products are sold. Since entering into the Basic Agreement on Business Collaboration in Octob

Invivoscribe® Launches LeukoStrat® KMT2A + MRD Assay to Advance High-Sensitivity Leukemia Testing in Clinical Trials and Patient Management Worldwide5.2.2026 06:30:00 CET | Press release

Invivoscribe, a leader in precision medicine and measurable residual disease (MRD) testing, today announced the addition of the LeukoStrat®KMT2A + MRD Assay and Software to its industry-leading oncology portfolio. The assay leverages digital PCR (dPCR) to support both screening and precise longitudinal MRD monitoring for KMT2A rearrangements in acute myeloid leukemia (AML) subjects. This quantitative test is currently available for research use in clinical trials and as a stand-alone kit for purchase by our global customers, and will soon be available as a service in our regional LabPMM® laboratories worldwide. The assay is available to detect key AML-associated KMT2A rearrangements, which account for the vast majority of KMT2A fusion partners in AML1 and those most commonly targeted in menin-inhibitor clinical development programs. Later this year, the assay will be enhanced with four additional KMT2A rearrangements which are frequently found in acute lymphocytic leukemia (ALL), expan

VeriSilicon Enhanced ISP8200-FS Series IP Achieves ASIL B Functional Safety Certification5.2.2026 01:00:00 CET | Press release

Enabling Next-Generation High-Performance Automotive Camera Systems VeriSilicon (688521.SH) today announced its latest enhanced versions of Image Signal Processing (ISP) IP ISP8200-FS series, ISP8200-ES and ISP8200L-ES, featuring improved performance and energy efficiency to better support complex automotive camera systems. These enhanced IPs have successfully achieved ISO 26262 ASIL B functional safety certifications issued by TÜV NORD, an international inspection and certification institution, further validating their suitability and reliability for ADAS and autonomous driving applications. The latest enhanced ISP8200-FS series IP can operate at up to 1.2 GHz and support data processing from up to 16 image sensors. It significantly improves the performance of multi-camera scheduling, enabling flexible data-access capabilities and efficient hardware pipeline utilization for automotive camera systems. The enhanced series IP integrates image processing technologies including Color Noise

Kinaxis Inc. to Host Fourth Quarter 2025 Financial Results Conference Call on March 5, 20264.2.2026 22:30:00 CET | Press release

Kinaxis® Inc. (TSX:KXS), a global leader in supply chain orchestration, today announced that it has scheduled its conference call to discuss the financial results for its fourth quarter and year ended December 31, 2025. The call will be hosted on Thursday, March 5 at 8:30 a.m. Eastern Time by Razat Gaurav, chief executive officer, and Blaine Fitzgerald, chief financial officer, followed by a question and answer period. The Company will report its financial results for the fourth quarter and year after the close of markets on Wednesday, March 4, 2026. CONFERENCE CALL DETAILS DATE: Thursday, March 5, 2026 TIME: 8:30 a.m. Eastern Time WEBCAST: https://events.q4inc.com/attendee/567578009 (available for three months) About Kinaxis Kinaxis is a leader in modern supply chain orchestration, powering complex global supply chains and supporting the people who manage them. Our powerful, AI-infused supply chain orchestration platform, Maestro, combines proprietary technologies and techniques that

Mainstay Medical Announces Exclusive Coverage of ReActiv8® by Blue Cross Blue Shield of North Dakota4.2.2026 22:30:00 CET | Press release

Mainstay Medical Holdings plc today announced that Blue Cross Blue Shield of North Dakota has established favorable coverage for the company’s ReActiv8 Restorative NeurostimulationTM therapy for the treatment of intractable chronic low back pain. The policy went into effect in January 2026 and specifies that ReActiv8 is the only therapy considered medically necessary by the policy when the conditions for coverage are met. “We are pleased that another Blue Cross Blue Shield payer has joined Anthem in making ReActiv8 available to well-selected patients after reviewing the large body of clinical evidence we have built,”said Jason Hannon, CEO of Mainstay Medical. “Patients with intractable chronic low back pain are desperately seeking durable solutions, and ReActiv8 has proven to be a safe and effective solution through six clinical studies with 633 patients treated and 1,950 patient-years of follow-up, including two multi-center, randomized controlled clinical studies. We look forward to

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye